TimoD implant for glaucoma or high eye pressure during cataract surgery
Tests a timolol implant placed in the eye of adults with glaucoma.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery
Key facts
- Where
- Panama City, PanamaSee the site
- Phase
- Phase 1/2
Where in Panama
- Panama Eye CenterPanama City, PanamaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- EyeD Pharma
- Trial code
- NCT07036510
- Record updated
- 30 July 2026
- Original description
The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery.Read full original descriptionShow less
Early Feasibility Study to Evaluate the Safety and Efficacy of a New Timolol Sustained-Release Intraocular Implant (TimoD) in Participants With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) Undergoing Cataract Surgery
The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery.
The study is conducted in two stages. The first stage (Stage 1/Phase 1) is intended to study the safety of 3 different doses of the study medication (called TimoD implant). The second stage (Stage 2/Phase 2) of the study is intended to study in greater detail the efficacy and safety of the 3 doses of the TimoD implant in comparison to a standard approved medication, timolol eye drops for 3 years.
Inclusion: Capable of giving signed informed consent; In good general and mental health without ongoing clinically significant abnormalities in medical history; Open-angle glaucoma or ocular hypertension and age-related cataract eligible for intra-capsular IOL placement; Successful, uncomplicated cataract surgery.
Exclusion: Participants using any systemic or topical drug known to interfere with visual performance, pupil dilation, or iris structure; Significant risks caused by washout of ocular hypotensive medications; Subjects with a history of hypersensitivity or contraindications to β- blockers; Clinically significant ocular pathology other than OHT, glaucoma and cataract.